Merck Announces First-Quarter 2020 Financial Results
KENILWORTH, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the
Read morePharmaceutical Company News
The latest news from the pharmaceutical sector. Covering the latest breaking news, encompassing company news from leading pharmaceutical companies and related companies.
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA’ Committee of Orphan Medicinal Products | Adaptimmune Therapeutics Plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy
Read moreNew 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
Post-hoc analysis from 6 years of Phase III open-label extension studies showed OCREVUS treatment reduced the risk of needing a
Read moreNovartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
DisclaimerThese materials contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking
Read moreFederal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound
NEW BRUNSWICK, NJ – April 27, 2020: Johnson & Johnson (“the Company”) (NYSE: JNJ) today announced that U.S. District Judge
Read moreSanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients Independent Data Monitoring Committee recommended
Read moreAmgen Announces Webcast Of 2020 First Quarter Financial Results
THOUSAND OAKS, Calif., April 27, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results
Read moreRegeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ — Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only
Read moreMerck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
KENILWORTH, N.J. & SEATTLE-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for
Read moreDaiichi Sankyo Announces Share Split, Partial Amendment to the Articles of Incorporation, and Forecast of Annual Dividend per Share for the Year Ending March 31, 2021 - Media & Investors
For Immediate Release 2020.04.27 Company name: DAIICHI SANKYO COMPANY, LIMITEDRepresentative: Sunao Manabe, Representative Director, President and CEO(Code no.: 4568, First
Read moreTakeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations
Cambridge, MASS. & Osaka, JAPAN, April 27, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S.
Read moreSanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of
Read moreVertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies | Vertex Pharmaceuticals
Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy,
Read morePhase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival | Regeneron Pharmaceuticals Inc.
TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ — Libtayo decreased the risk of death by 32.4% compared to chemotherapy
Read moreFirst Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
KENILWORTH, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim
Read moreDaiichi Sankyo Announces Removal of Contaminated Soil Storage Facility from Site of Former Yasugawa Plant in Japan - Media & Investors
For Immediate Release 2020.04.27 Company name: DAIICHI SANKYO COMPANY, LIMITEDRepresentative: Sunao Manabe, Representative Director, President and CEO(Code no.: 4568, First
Read moreJanssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two
Read moreSanofi at forefront of fight against COVID-19 in Q1 2020
Sanofi at forefront of fight against COVID-19 in Q1 2020 Rapid and decisive response to COVID-19 global health crisis Sanofi
Read moreStatement of Support on Access to New COVID-19 Tools
Johnson & Johnson fully endorses the goals of the Global Collaboration to Accelerate Development, Production and Equitable Access to New
Read moreApr 24,2020 | Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan | News | CHUGAI PHARMACEUTICAL CO., LTD.
TOKYO, April 24, 2020- Chugai Pharmaceutical Co., Ltd. announced that disposal of treasury shares was completed today, as we announced
Read moreLYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
KENILWORTH, N.J.-(BUSINESS WIRE)-AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced further positive
Read moreLynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
24 April 2020 07:00 BST Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments for this advanced
Read moreTakeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core Assets in Europe to Orifarm for up to approximately $670M USD
Osaka, JAPAN, April 24, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an
Read moreIncyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada
MONTREAL-(BUSINESS WIRE)-Apr. 24, 2020- Incyte (Nasdaq:INCY) announces the appointment of Christine Lennon as the General Manager for Incyte Biosciences Canada,
Read more